Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (13637)	1/23/1998 1:56:00 AM
From: Andrew H	Read Replies (2) \| Respond to of 32384

>>Andy, I have not found the PFE story on Droloxifene linked to LGND by any of the wire services yet (PRNewswire and Reuters). I have to check out Dow Jones.<< That's encouraging--maybe we should write jill and ask her to delete our posts from SI before anyone reads them. (:>) The more I think about it, the more I think it benefits LGND. 3% royalty vs. 1%, and a FAR LARGER market for osteo prevention than for advanced breast cancer. Really, to the extent that droloxifene is a factor for LGND (a fairly small extent, IMO, except for milestones which will probably not be affected), this is clearly a plus for LGND when a little thought is applied to the situation.